Kyntheum could soon get NICE approval for psoriasis

[Fred]

Following on from this report Scotland says no for Kyntheum to treat psoriasis The National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending Kyntheum (brodalumab) for psoriasis.

Quote:

---

Brodalumab is recommended as an option for treating plaque psoriasis in adults, only if:

The disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10.

The disease has not responded to other systemic therapies, including ciclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet A radiation), or these options are contraindicated or not tolerated.

The company provides the drug with the discount agreed in the patient access scheme.

Source: nice.org.uk

Kyntheum / Siliq (brodalumab)